Imfinzi has received priority review by the FDA for the treatment of lung cancer 

AstraZeneca on Thursday the US Food and Drug Administration (FDA) said its top-selling cancer drug Imfinzi has received priority review for patients with limited-stage small-cell lung cancer in the United States.

Teile diesen Beitrag:

BELIEBTE BEITRÄGE
FOLGEN SIE UNS
Like uns auf Facebook
Folge uns auf Twitter
Abonniere unseren Kanal
Tick Tack
LIVEÜBERTRAGUNG